General Information of Drug (ID: DMLUM3Y)

Drug Name
ONO-4641 Drug Info
Synonyms Sphingosine-1-phosphate agonist (tablet, mutiple sclerosis), Ono
Indication
Disease Entry ICD 11 Status REF
Rheumatoid arthritis FA20 Phase 2 [1]
Cross-matching ID
PubChem CID
11502996
CAS Number
CAS 891859-12-4
TTD Drug ID
DMLUM3Y

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Siponimod DM2R86O Multiple sclerosis 8A40 Approved [3]
Fingolimod DM5JVAN Multiple sclerosis 8A40 Approved [4]
Ozanimod DMT6AM2 Multiple sclerosis 8A40 Approved [5]
Etrasimod DMT0A3Y Ulcerative colitis DD71 Approved [6]
Ponesimod DMEAOYJ Multiple sclerosis 8A40 Approved [7]
MT-1303 DMSE9TH Crohn disease DD70 Phase 2 [8]
KRP-203 DMOW9X2 Cutaneous lupus erythematosus EB5Z Phase 2 [2]
VTX-002 DMZ8Z5A Ulcerative colitis DD71 Phase 2 [9]
CBP-307 DM3TH6Y Ulcerative colitis DD71 Phase 2 [10]
Sphingosine-1-phosphate DMJCQKA Acne vulgaris ED80 Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sphingosine-1-phosphate receptor 1 (S1PR1) TT9JZCK S1PR1_HUMAN Agonist [2]

References

1 ClinicalTrials.gov (NCT01226745) A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis. U.S. National Institutes of Health.
2 Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
4 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
8 Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis. CNS Drugs. 2015 Jul;29(7):565-75.
9 Clinical pipeline report, company report or official report of Ventyx Biosciences
10 Clinical pipeline report, company report or official report of Connect Biopharma
11 Exploration of amino alcohol derivatives as novel, potent, and highly selective sphingosine-1-phosphate receptor subtype-1 agonists. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2520-4.